A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Inclusion Criteria:

1. Patients ≥ 18 years old and ≤ 65 years old

2. Newly diagnosed as AML patients according to 2016 World Health Organization (WHO)classification;

3. Patients without receiving prior therapy for AML;

4. Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3;

5. Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartateaminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN

6. Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Scr (serum creatinine) ≦2ULN

7. Heart function: left ventricular ejection fraction ≧45%

8. Patients must participate in this clinical trial voluntarily and sign an informedconsent form.

Exclusion Criteria:

1. Acute promyeloid leukemia；

2. AML with central nervous system (CNS) infiltration；

3. Patients have received prior hypomethylating agents (HMA) therapy formyelodysplastic syndrome (MDS) and progressed to AML；

4. Patients with a life expectancy <3 months

5. Patients with uncontrolled active infection;

6. HIV infection;

7. Evidence of other clinically significant uncontrolled condition(s) including, butnot limited to: a) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiringtreatment; b) An active second cancer that requires treatment within 6 months ofstudy entry.

8. Female who are pregnant, breast feeding or childbearing potential.

9. Patients deemed unsuitable for enrollment by the investigator.